Debate on Weight Loss Drug Prices and Healthcare System Issues

This chapter explores the controversy surrounding the steep costs of weight loss medications like Ozempic and Wigovi, featuring testimony from the CEO of Novo Nordisk. It highlights public frustration over pharmaceutical profits and the implications for the U.S. healthcare system.

Transcript

Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!

Get the app